SPY411.49+2.97 0.73%
DIA337.86+2.73 0.81%
IXIC13,900.19+70.88 0.51%

BRIEF-Imara Announces Opening Of Higher Dose Arms In Global Phase 2B Clinical Trials Of IMR-687 For Sickle Cell Disease And Beta-Thalassemia

· 03/17/2021 07:46
BRIEF-Imara Announces Opening Of Higher Dose Arms In Global Phase 2B Clinical Trials Of IMR-687 For Sickle Cell Disease And Beta-Thalassemia

- Imara Inc IMRA.O:

  • IMARA ANNOUNCES OPENING OF HIGHER DOSE ARMS IN GLOBAL PHASE 2B CLINICAL TRIALS OF IMR-687 FOR SICKLE CELL DISEASE AND BETA-THALASSEMIA

  • IMARA INC - EXPECT TO REPORT PRELIMINARY DATA FROM HIGHER DOSE ARMS OF IMR-687 AS PART OF PLANNED DATA READOUTS IN H2 2021

Source text for Eikon: ID:nGNX2XxfqL

Further company coverage: IMRA.O


((Reuters.Briefs@thomsonreuters.com;))